JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.